The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable ...

Phase 2 stage CT-388, a dual GLP-1/GIP receptor agonist injected ... It's difficult to judge if Roche can meet all the peak revenue targets it has set (see chart above), but the likelihood is ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what the ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist ... Roche/Genentech and sanofi-aventis. All grant and research support is managed by the University of California San Diego (CA, USA) and ...

In short, failing to make the GLP-1 drugs widely affordable and available to all Americans is the proverbial case of being penny-wise and pound-foolish (and yes, the pun is intended.) ...

In short, failing to make the GLP-1 drugs widely affordable and available to all Americans is the proverbial case of being penny-wise and pound-foolish (and yes, the pun is intended.) We’re over the ...